血脂异常管理与药物治疗的最新进展：综述
An Update on Dyslipidemia Management and Medications: A Review.
作者信息
Taher Ziad A, Taher Abdulrahman A, Radi Suhaib
机构信息
Department of Medicine, King Abdulaziz Medical City, Jeddah, SAU.
College of Medicine, University of Jeddah, Jeddah, SAU.
出版信息
Cureus. 2024 Mar 16;16(3):e56255. doi: 10.7759/cureus.56255. eCollection 2024 Mar.
Abstract
Dyslipidemia, characterized by abnormal lipid levels in the bloodstream, is a very common and underappreciated chronic disease associated with a significant cardiovascular disease burden. The management landscape for dyslipidemia has historically been static, with a sparse selection of therapeutic options. This article presents a comprehensive review of contemporary approaches to dyslipidemia management, focusing on therapeutic strategies and emerging interventions. We delineate the most current American Heart Association/American College of Cardiology & Canadian Cardiovascular Society guidelines and examine pivotal clinical trials that are shaping the contemporary approach to dyslipidemia management.
摘要
血脂异常是一种以血液中脂质水平异常为特征的非常常见但未得到充分重视的慢性病，与重大的心血管疾病负担相关。从历史上看，血脂异常的管理格局一直停滞不前，治疗选择很少。本文全面综述了血脂异常管理的当代方法，重点关注治疗策略和新兴干预措施。我们阐述了最新的美国心脏协会/美国心脏病学会和加拿大心血管学会指南，并审视了正在塑造当代血脂异常管理方法的关键临床试验。
相似文献
1
An Update on Dyslipidemia Management and Medications: A Review.
Cureus. 2024 Mar 16;16(3):e56255. doi: 10.7759/cureus.56255. eCollection 2024 Mar.
2
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE.
Endocr Pract. 2017 Apr;23(Suppl 2):1-87. doi: 10.4158/EP171764.APPGL.
3
Systematic Review for the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
J Am Coll Cardiol. 2019 Jun 25;73(24):3210-3227. doi: 10.1016/j.jacc.2018.11.004. Epub 2018 Nov 10.
4
Systematic Review for the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
Circulation. 2019 Jun 18;139(25):e1144-e1161. doi: 10.1161/CIR.0000000000000626. Epub 2018 Nov 10.
5
The Detection, Evaluation, and Management of Dyslipidemia in Children and Adolescents: A Canadian Cardiovascular Society/Canadian Pediatric Cardiology Association Clinical Practice Update.
Can J Cardiol. 2022 Aug;38(8):1168-1179. doi: 10.1016/j.cjca.2022.05.002.
6
Inclisiran: a small interfering RNA strategy targeting PCSK9 to treat hypercholesterolemia.
Expert Opin Drug Saf. 2022 Jan;21(1):9-20. doi: 10.1080/14740338.2022.1988568. Epub 2021 Oct 14.
7
Inclisiran for the treatment of dyslipidemia.
Expert Opin Investig Drugs. 2018 Mar;27(3):287-294. doi: 10.1080/13543784.2018.1442435. Epub 2018 Feb 22.
8
Novel aspects of PCSK9 and lipoprotein receptors in renal disease-related dyslipidemia.
Cell Signal. 2019 Mar;55:53-64. doi: 10.1016/j.cellsig.2018.12.001. Epub 2018 Dec 12.
9
2017 Focused Update of the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways.
J Am Coll Cardiol. 2017 Oct 3;70(14):1785-1822. doi: 10.1016/j.jacc.2017.07.745. Epub 2017 Sep 5.
10
Usefulness of alirocumab and evolocumab for the treatment of patients with diabetic dyslipidemia.
Proc (Bayl Univ Med Cent). 2018 Apr 11;31(2):180-184. doi: 10.1080/08998280.2018.1441255. eCollection 2018 Apr.
引用本文的文献
1
Chitosan-Based Nanoparticles Targeted Delivery System: In Treatment Approach for Dyslipidemia.
Int J Nanomedicine. 2025 May 24;20:6611-6636. doi: 10.2147/IJN.S517492. eCollection 2025.
本文引用的文献
1
Updated guidelines for the management of dyslipidemia and the prevention of cardiovascular disease in adults by pharmacists.
Can Pharm J (Ott). 2023 Apr 21;156(3):117-127. doi: 10.1177/17151635231164989. eCollection 2023 May-Jun.
2
Medical Nutrition Therapy Provided by Dietitians is Effective and Saves Healthcare Costs in the Management of Adults with Dyslipidemia.
Curr Atheroscler Rep. 2023 Jun;25(6):331-342. doi: 10.1007/s11883-023-01096-0. Epub 2023 May 11.
3
Inclisiran-A Revolutionary Addition to a Cholesterol-Lowering Therapy.
Int J Mol Sci. 2023 Apr 6;24(7):6858. doi: 10.3390/ijms24076858.
4
Inclisiran: A Review in Hypercholesterolemia.
Am J Cardiovasc Drugs. 2023 Mar;23(2):219-230. doi: 10.1007/s40256-023-00568-7. Epub 2023 Mar 4.
5
PCSK9 inhibitors and ezetimibe with or without statin therapy for cardiovascular risk reduction: a systematic review and network meta-analysis.
BMJ. 2022 May 4;377:e069116. doi: 10.1136/bmj-2021-069116.
6
Icosapent ethyl: scientific and legal controversies.
Open Heart. 2021 Apr;8(1). doi: 10.1136/openhrt-2021-001616.
7
2021 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in Adults.
Can J Cardiol. 2021 Aug;37(8):1129-1150. doi: 10.1016/j.cjca.2021.03.016. Epub 2021 Mar 26.
8
Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk: The STRENGTH Randomized Clinical Trial.
JAMA. 2020 Dec 8;324(22):2268-2280. doi: 10.1001/jama.2020.22258.
9
Efficacy and safety of lowering LDL cholesterol in older patients: a systematic review and meta-analysis of randomised controlled trials.
Lancet. 2020 Nov 21;396(10263):1637-1643. doi: 10.1016/S0140-6736(20)32332-1. Epub 2020 Nov 10.
10
New Pharmacological Approaches to Target PCSK9.
Curr Atheroscler Rep. 2020 Jun 3;22(7):24. doi: 10.1007/s11883-020-00847-7.
Zotero 插件